<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<schemaVersion>X0202</schemaVersion>
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0000000000-00-000000</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0002099513</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>2</amendmentNo>
<securitiesClassTitle>Common Stock, $0.00001 par value</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>09/30/2026</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001557746</issuerCik>
<issuerName>Aclaris Therapeutics, Inc.</issuerName>
<issuerCusips>
<issuerCusipNumber>00461U105</issuerCusipNumber>
</issuerCusips>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>701 Lee Road, Suite 103</com:street1>
<com:city>Wayne</com:city>
<com:stateOrCountry>PA</com:stateOrCountry>
<com:zipCode>19087</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Biosion, Inc.</reportingPersonName>
<citizenshipOrOrganization>F4</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>7521300</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>7521300</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>7521300</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>4.7</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>(1) The value in rows (5) and (7) represents 7,521,300 shares of common stock of record by Bonita Biotech (HK) Limited. Bonita Biotech (HK) Limited is wholly owned by Biosion, Inc.&#13;
&#13;
(2) Percent of class represented by amount in row (9) is calculated based on 158,612,149 issued and outstanding shares of Common Stock of the Issuer as at October 30, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Bonita Biotech (HK) Ltd</reportingPersonName>
<citizenshipOrOrganization>K3</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>7521300</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>7521300</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>7521300</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>4.7</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>(1) The value in rows (5) and (7) represents 7,521,300 shares of common stock of record by Bonita Biotech (HK) Limited.&#13;
&#13;
(2) Percent of class represented by amount in row (9) is calculated based on 158,612,149 issued and outstanding shares of Common Stock of the Issuer as at October 30, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Aclaris Therapeutics, Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>701 Lee Road, Suite 103, Wayne, Pennsylvania, 19087</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>1.	Biosion, Inc.&#13;
&#13;
2.	Bonita Biotech (HK) Limited</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>For all reporting persons:&#13;
&#13;
5th Floor, Building D&#13;
3-1 Zhongdan Unit, South Longshan Rd&#13;
Jiangbei New District&#13;
Nanjing, Jiangsu, China</principalBusinessOfficeOrResidenceAddress>
<citizenship>Biosion, Inc. is established under the laws of the People's Republic of China.&#13;
&#13;
Bonita Biotech (HK) Limited is incorporated under the laws of Hong Kong.</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>The information for each reporting person contained in Items 5-9 of the cover pages is incorporated herein by reference.</amountBeneficiallyOwned>
<classPercent>The information for each reporting person contained in Item 11 of the cover pages is incorporated herein by reference.</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>The information for each reporting person contained in Item 5 of the cover pages is incorporated herein by reference.</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>The information for each reporting person contained in Item 6 of the cover pages is incorporated herein by reference.</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>The information for each reporting person contained in Item 7 of the cover pages is incorporated herein by reference.</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>The information for each reporting person contained in Item 8 of the cover pages is incorporated herein by reference.</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>N</notApplicableFlag>
<classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>Biosion, Inc.</reportingPersonName>
<signatureDetails>
<signature>/s/ MINGJIU CHEN</signature>
<title>MINGJIU CHEN / CEO</title>
<date>11/16/2026</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Bonita Biotech (HK) Ltd</reportingPersonName>
<signatureDetails>
<signature>/s/ MINGJIU CHEN</signature>
<title>MINGJIU CHEN / Director</title>
<date>11/16/2026</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
